Suchergebnisse - "Sung, J J Y"

PubPharm (6)

1

Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

enthalten in: Alimentary pharmacology & therapeutics | 2018

von Chuang, W. | Jia, J. | Chan, H. | +13

CommentIn: Aliment Pharmacol Ther. 2018 Jun;47(11):1556-1557. - PMID 29878418

2

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

enthalten in: Hepatology (Baltimore, Md.) | 2011

von Liaw, Y. | Jia, J. | Chan, H. | +14

3

Randomised clinical trial : efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance

enthalten in: Alimentary pharmacology & therapeutics | 2011

von Sun, J. | Hou, J. | Xie, Q. | +14

4

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

enthalten in: Alimentary pharmacology & therapeutics | 2010

von Chan, H. | Wong, V. | Chim, A. | +3

5

Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese

enthalten in: Alimentary pharmacology & therapeutics | 2006

von Chan, H. | Tse, A. | Zhang, M. | +4

6

Systematic review : treatment of chronic hepatitis B virus infection by pegylated interferon

enthalten in: Alimentary pharmacology & therapeutics | 2005

von Hui, A. | Chan, H. | Cheung, A. | +2

1
[1]